Activating types 1 and 2 angiotensin II receptors modulate the hypertrophic differentiation of chondrocytes  by Tsukamoto, Ichiro et al.









 j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / f e b s o p e n b i o 
Activating types 1 and 2 angiotensin II receptors modulate the hypertrophic differ-
entiation of chondrocytes  
Ichiro Tsukamoto a , * , Shinji Inoue a , Takeshi Teramura b , Toshiyuki Takehara b , Kazuhiro Ohtani a , Masao Akagi a
a Department of Orthopaedic Surgery, Faculty of Medicine, Kinki University, 377-2 Ohno-Higashi, Osaka-Sayama City, Osaka 589-8511, Japan 
b Division of Cell Biology for Regenerative Medicine, Institute of Advanced Clinical Medicine, Kinki University, 377-2 Ohno-Higashi, Osaka-Sayama City, Osaka 589-8511, Japan 
a r t i c l e i n f o 
Article history: 
Received 25 March 2013 
Received in revised form 25 May 2013 





Angiotensin II type 1 receptor 
Angiotensin II type 2 receptor 
a b s t r a c t 
A local tissue-speciﬁc renin–angiotensin system (local RAS) has been identiﬁed in many organs. How-
ever, no report has described the role of a local RAS in the hypertrophic differentiation of chondrocytes.
To examine the role of a local RAS in the hypertrophic differentiation, we activated angiotensin II type
1 receptor (AT1R) and angiotensin II type 2 receptor (AT2R) separately in the cell line ATDC5, which in-
volves differentiation from mesenchymal stem cells to hypertrophic chondrocytes. Activation of AT1R
suppressed and activation of AT2R enhanced the expression of markers of hypertrophic differentiation,
including type X collagen, matrix metalloproteinase 13 and runt-related transcription factor 2. 
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical





































 1. Introduction 
Renin was ﬁrst identiﬁed in 1898 by Tigerstedt and Bergman [ 1 ],
and the renin–angiotensin system (RAS) has been studied extensively
since then. Researchers ﬁrst studied the RAS as a systemic cardiovas-
cular homeostatic system [ 2 ]. Thus, inhibitors of the systemic RAS
have become important clinical tools in the treatment of renal and
cardiovascular diseases such as hypertension, heart failure and di-
abetic nephropathy [ 3 ]. It is now known that an RAS also operates
locally. A local tissue-speciﬁc RAS (local RAS) has been identiﬁed re-
cently in many organs [ 3 ]. A local RAS has also been shown to exert
a distinct biological action in each organ. For example, in the ovary,
components of the local RAS comprise reaction pathways between
theca and granulosa cells to inhibit estradiol formation by the theca
cells [ 4 ]. In the uterus, a local RAS controls uterine blood ﬂow dur-
ing pregnancy [ 5 ]. In the musculoskeletal system, expression of a
local RAS has been found in the fracture callus formed in the healing
process [ 6 ] and in the synovium of individuals with chronic arthri-
tis [ 7 ]. Angiotensin II (Ang II) accelerates osteoporosis by activating
osteoclasts [ 8 ], and treatment with angiotensin-converting enzyme
inhibitors is associated with a reduced fracture risk [ 9 ]. A local RAS is
also expressed in osteoblasts of the fetal rat calvaria [ 10 ], suggesting
the existence of a local RAS in embryonic osteoblasts. However, it is* Corresponding author. Tel.: + 81 72 366 0221; fax: + 81 72 366 0206. 









2211-5463    c© 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of Europe
http://dx.doi.org/10.1016/j.fob.2013.07.001 still unknown whether a local RAS is functional in the hypertrophic
differentiation of chondrocytes. Here we investigated the role of a
local RAS in hypertrophic differentiation using the ATDC5 cell line.
This involves the differentiation of mesenchymal stem cells to form
calciﬁed hypertrophic chondrocytes. 
2. Materials and methods 
2.1. Cell culture 
The ATDC5 cell line was obtained from the Riken Cell Bank (Rika-
gakukenkyusyo, Tsukuba, Japan). Cells were cultured in a 1:1 mixture
of Dulbecco’s modiﬁed Eagle’s medium (DMEM) and Ham’s F-12 with
5% fetal bovine serum (FBS) and 3 × 10 −8 M sodium selenite. The
cells were maintained at 37 ◦C in a 5% CO 2 atmosphere and grown as
a monolayer. They were ﬁrst plated at 1.2 × 10 5 cells per 35 mm well
and then allowed to proliferate for about 3 days until they reached
conﬂuence. Then, cells were induced to differentiate in a 1:1 mixture
of DMEM and Ham’s F-12 containing 5% FBS, 10 μg / ml human trans-
ferrin, 3 × 10 −8 M sodium selenite and 10 μg / ml bovine insulin. The
culture medium was replaced every other day. The cells were allo-
cated into 11 groups (groups A–K). Cells allocated to groups A–I were
treated with various reagents on Day 14. Cells allocated to group
J were treated with various reagents on Day 10. Cells allocated to
group K were treated with various reagents on Day 21. Cells assigned
to group A were treated with phosphate-buffered saline (PBS) alone
as controls. Group B was treated with 0.1 μg / ml Ang II. Group C was
treated with 1.0 μg / ml Ang II. Group D was treated with 1.0 μg / ml Ang
II and 1.0 μg / ml Olmesartan, an angiotensin II type 1 receptor (AT1R)
inhibitor. Group E was treated with 1.0 μg / ml Ang II and 1.0 μg / ml
PD123319, an angiotensin II type 2 receptor (AT2R) inhibitor. Groupan Biochemical Societies. Open access under CC BY-NC-ND license.
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Fig. 1. Expression of local RAS components during the hypertrophic differentiation of ATDC5 cell line. (A) ANG began to be expressed in the proliferating phase and maintained 
expression during the hypertrophic phase. (B) AT1R was expressed intensely during proliferation. (C and D) ACE1 (C) and AT2R (D) were expressed intensely in the hypertrophic 
phase. (E) On Day 14 when both AT1R and AT2R were expressed, the relative expression of AT1R was about 25 times that of AT2R. (F) Western blot analysis showed that ANG, 
AT1R and ACE1 were expressed in both the proliferating and hypertrophic phases and that AT2R was expressed intensely in the hypertrophic phase. * P < 0.05 between treatments. 























a (control) was cultured without adding any agents. Group G was 
reated with 0.1 μg / ml Olmesartan; group H was treated with 1.0 μg / 
l Olmesartan, and group I was treated with 10 μg / ml Olmesartan. 
roup J was treated with 1.0 μg / ml Ang II and 1.0 μg / ml PD123319 
r with 1.0 μg / ml Ang II and 1.0 μg / ml Olmesartan on Day 10. Group
 was treated with 1.0 μg / ml Ang II and 1.0 μg / ml PD123319 or with
.0 μg / ml Ang II and 1.0 μg / ml Olmesartan on Day 21. Olmesartan 
as obtained from Daiichi-Sankyo Co., Ltd. (Tokyo, Japan). PD123319 
ditriﬂuoroacetate) was purchased from Wako Pure Chemical Indus- 
ries (Osaka, Japan). 
.2. Quantitative reverse transcription polymerase chain reaction 
QRT–PCR) 
Total RNA was extracted from ATDC5 cells using TRIzol (Invit- 
ogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. 
ells to which agents were administered were treated with TRIzol 
 h after the administration. The extracted total RNA was reverse- 
ranscribed using random primers under standard conditions with 
 high-capacity cDNA reverse transcription kit (Applied Biosystems, 
oster City, CA, USA). This ﬁrst strand cDNA (1:10 dilution) was 
mpliﬁed. QRT–PCR was performed using Perfect real-time SYBR 
reen II (Takara Bio, Inc., Shiga, Japan). PCR ampliﬁcations were 
erformed with the Thermal Cycler Dice Real Time PCR System 
Takara Bio, Inc.) at 95 ◦C for 15 s, followed by 40 cycles of 95 ◦C for 5 s
nd 60 ◦C for 30 s. Relative quantiﬁcation of the gene of interest was normalized to the housekeeping gene for β-actin in the comparative 
CT method. To quantify the relative expression of each gene, C t 
values were normalized against the endogenous reference ( C t = C t 
target −C t β-actin) and were compared with a calibrator using 
the C t method ( C t = C t sample −C t calibrator). We used 
the average C t value for untreated ATDC5 cell line as a calibrator. 
All experiments included negative controls, which consisted of no 
cDNA for each primer pair. Primer pairs used in this study were 
as follows: AT1R, forward primer 5 ′ -TGCTCACGTGTCTCAGCATC-3 ′ 
and reverse primer 5 ′ -TTTGGCCACCAGCATCGTG-3 ′ ; AT2R, forward 
primer 5 ′ -TAAGCTGATTTATGATAACTGC-3 ′ and reverse primer 
5 ′ -ATATTGAACTGCAGCAACTC-3 ′ ; angiotensin-converting enzyme 
1 (ACE1), forward primer 5 ′ -AACGAAGCCTACAGACAAGAC-3 ′ and 
reverse primer 5 ′ -AGGCATGGAGGTTCAGGTAG-3 ′ ; angiotensino- 
gen (ANG), forward primer 5 ′ -TCAGTACAGACAGCACCCTAC-3 ′ 
and reverse primer 5 ′ -TGGACTCCAGGCAGCTGAG-3 ′ ; type X col- 
lagen (Col.X), forward primer 5 ′ - CGCCATAAAGAGTAAAGGGA- 
3 ′ and reverse primer 5 ′ -ACTTCCATAGCCTGGCTTG-3 ′ ; ma- 
trix metalloproteinase 13 (MMP13), forward primer 5 ′ - 
AAGATGTGGAGTGCCTGATG-3 ′ and reverse primer 5 ′ - 
TGGGACATATCAGGAGTATAG-3 ′ ; runt-related transcription factor 
2 (Runx2), forward primer 5 ′ -GTTCAACGATCTGAGATTTGTG-3 ′ 
and reverse primer 5 ′ -GGATTTGTGAAGACTGTTATGG-3 ′ ; β-actin, 
forward primer 5 ′ -TTCCAGCCTTCCTTCTTG-3 ′ and reverse primer 
5 ′ -GTCACACTTCATGATGGAATTG-3 ′ . 
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Fig. 2. Expression of Col.X in the ATDC5 cell line treated with various agents on Day 14. (A) Ang II downregulated the mRNA expression of Col.X in a concentration-dependent 
manner. (B) When cells were treated with Olmesartan, Ang II upregulated the mRNA expression of Col.X. (C) When cells were treated with PD123319, Ang II downregulated the 
mRNA expression of Col.X. (D) Western blot analysis showed that Ang II upregulated the expression of Col.X when cells were treated with Olmesartan and that Ang II downregulated 
the expression of Col.X when cells were treated with PD123319. (E) Western blotting detection of Col.X showed signiﬁcant differences between treatments. The molar concentration 
ratios of antagonists to agonist were 2.32 (1.0 μg / ml Olmesartan / 1.0 μg / ml AngII) and 1.77 (1.0 μg / ml PD123319 / 1.0 μg / ml AngII). * P < 0.05 between treatments. Abbreviations: 
Col.X, type X collagen; Ang II, angiotensin II. 
Fig. 3. Expression of Col.X in the ATDC5 cell line treated with Olmesartan on Day 
14. Adding 0.1 and 1.0 μg / ml Olmesartan made no signiﬁcant changes to the mRNA 
expression of Col.X. Adding 10 μg / ml Olmesartan upregulated the mRNA expression 




























 2.3. Western blot analysis 
ATDC5 cells were homogenized in sodium dodecyl sulfate (SDS)
buffer (4% SDS, 125 mM tris–glycine, 10% 2-mercaptoethanol, 2% bro-
mophenol blue in 30% glycerol) and subjected to polyacrylamide gel
electrophoresis in the presence of SDS followed by electrotransferonto polyvinylidene diﬂuoride membranes (Hybond-P; Amersham
Pharmacia Biotech, Buckinghamshire, UK). Cells to which agents were
administered were homogenized in SDS buffer 36 h after the ad-
ministration. The membranes were blocked overnight with Block
Ace (Dainippon Sumitomo Pharma, Osaka, Japan) and treated with
a primary antibody overnight at 4 ◦C. Primary antibodies were di-
luted to 1:10,000 with PBS. The membranes were then treated
with horseradish peroxidase-conjugated secondary antibodies for 1 h
while being shaken gently at room temperature. Secondary antibod-
ies were diluted 1:50,000 with PBS. Detection was realized by en-
hanced chemiluminescence (ECL) with an ECL Plus western blotting
detection system (Amersham Pharmacia Biotech, Buckinghamshire,
UK) and a charge-coupled-device-based chemiluminescent analyzer,
LAS 4000 (GE Healthcare UK Ltd., Buckinghamshire, UK). Relative
expression levels were quantiﬁed by normalizing western blot sig-
nals to the housekeeping gene for actin. Primary antibodies were
as follows: anti-actin goat polyclonal antibody (Santa Cruz Biotech-
nology, Dallas, TX, USA, sc-1616); anti-ANG rabbit monoclonal anti-
body (Abcam, Cambridge, UK, ab108334); anti-ACE1 goat polyclonal
antibody (Santa Cruz Biotechnology, sc-12187); anti-AT1R goat poly-
clonal antibody (Santa Cruz Biotechnology, sc-31181); anti-AT2R rab-
bit polyclonal antibody (Santa Cruz Biotechnology, sc-9040); and anti-
Col.X rabbit polyclonal antibody (EMD Millipore, Billerica, MA, USA,
#234196-500UL). Secondary antibodies were as follows: anti-goat
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Fig. 4. Expression of Col.X in the ATDC5 cell line treated with various agents on Days 10 and 21. (A) When cells were treated with PD123319, Ang II downregulated the mRNA 
expression of Col.X on Day 10. When cells were treated with Olmesartan, adding Ang II made no signiﬁcant changes in the mRNA expression of Col.X on Day 10. (B) When cells were 
treated with PD123319, adding Ang II made no signiﬁcant changes to the mRNA expression of Col.X on Day 21. When cells were treated with Olmesartan, Ang II upregulated the 
mRNA expression of Col.X on Day 21. The molar concentration ratios of antagonists to agonist were 2.32 (1.0 μg / ml Olmesartan / 1.0 μg / ml AngII) and 1.77 (1.0 μg / ml PD123319 / 1.0 






































agG horseradish peroxidase-conjugated donkey antibody (Santa Cruz 
iotechnology, sc-2020) for actin, ACE1 and AT1R detection; and anti- 
abbit-IgG horseradish peroxidase-conjugated goat antibody (Santa 
ruz Biotechnology, sc-2004) for ANG, AT2R and Col.X detection. 
.4. Statistical analysis 
All experiments were performed eight times. Results are presented 
s the mean ± SD and were processed using Stat View 5.0 statistical 
oftware. Differences between results were evaluated using Student’s 
 test or Dunnett’s test, and P < 0.05 was considered statistically sig- 
iﬁcant. 
. Results 
We ﬁrst examined the chronological mRNA expression levels of 
NG, ACE1, AT1R and AT2R in ATDC5 cells without any agents (group 
) using QRT–PCR analysis. The mRNA expression of ANG began to 
ncrease in the proliferating phase and maintained expression during 
he hypertrophic phase with a peak on Day 14 ( Fig. 1 A). The mRNA 
xpression of AT1R increased intensely in the proliferating phase with 
 peak on Day 10 ( Fig. 1 B). Thus, AT1R was still expressed in the early 
eriod of hypertrophy. The mRNA expression of ACE1 began to in- 
rease on Day 10 and kept increasing ( Fig. 1 C). The mRNA expression 
f AT2R began to increase on Day 14 and increased abruptly on Day 
1 ( Fig. 1 D). Thus, AT2R was expressed predominantly in the hyper- 
rophic phase. On Day 14, when both AT1R and AT2R were expressed, 
he relative mRNA expression of AT1R was about 25 times that of 
T2R ( Fig. 1 E). We also examined the chronological protein synthesis 
f local RAS components without any agents using western blot anal- 
sis (group F). ANG, AT1R and ACE1 were expressed as synthesized 
roteins in both the proliferating and hypertrophic phases. However, 
T2R was not produced during proliferation but was produced in- 
ensely in the hypertrophic phase as synthesized protein ( Fig. 1 F). 
hus, we conﬁrmed that ANG, ACE1, AT1R and AT2R were expressed 
n the early period of the hypertrophic phase. Then, to examine the 
unction of the local RAS in hypertrophic differentiation, we admin- 
stered speciﬁc AT1R and AT2R inhibitors to ATDC5 cells as described 
bove. Because the results of QRT–PCR analysis for the local RAS com- 
onents suggested that both AT1R and AT2R were expressed on Day 
4, we chose this as the day for administration. The mRNA expression 
f Col.X was downregulated in a concentration-dependent manner 
ith a signiﬁcant difference from the control cells (group A) when 
dding Ang II on Day 14 (groups B and C; Fig. 2 A). Ang II treatment upregulated the mRNA expression of Col.X with a signiﬁcant differ- 
ence from the control cells (group A) treated with Olmesartan (group 
D; Fig. 2 B). On the other hand, Ang II downregulated the expression 
of Col.X with a signiﬁcant difference from the control cells (group A) 
treated with PD123319 (group E; Fig. 2 C). We also examined the pro- 
tein synthesis of Col.X with various agents using western blot analysis 
on Day 14. Ang II upregulated the expression of Col.X with a signiﬁcant 
difference from the control cells (group A) treated with Olmesartan 
(group D; Fig. 2 D and E). On the other hand, Ang II treatment down- 
regulated the expression of Col.X with a signiﬁcant difference from 
the control cells (group A) treated with PD123319 (group E; Fig. 2 D 
and E). We also examined the side effects of adding Olmesartan. We 
administered 0.1, 1.0 and 10 μg / ml Olmesartan on Day 14. Adding 
the two lower doses did not interfere with the expression of Col.X 
(groups G and H; Fig. 3 ). However, treatment with 10 μg / ml Olme- 
sartan without adding AngII upregulated the expression of Col.X with 
a signiﬁcant difference from the control cells (group I; Fig. 3 ). We also 
administered agents on Days 10 and 21. On Day 10, Ang II treatment 
downregulated the expression of Col.X with a signiﬁcant difference 
from the control cells treated with PD123319 (group J; Fig. 4 A). How- 
ever, Ang II treatment made no signiﬁcant change to cells treated with 
Olmesartan on Day 10 (group J; Fig. 4 A). On Day 21, Ang II treatment 
made no signiﬁcant change to cells treated with PD123319 (group 
K; Fig. 4 B). However, Ang II treatment upregulated the expression 
of Col.X with a signiﬁcant difference from the control cells treated 
with Olmesartan (group K; Fig. 4 B). Additionally, we examined the 
mRNA expression levels of MMP13 and Runx2 using QRT–PCR anal- 
ysis. Ang II upregulated the mRNA expressions of MMP13 and Runx2 
with a signiﬁcant difference from the control cells (group A) treated 
with Olmesartan (group D; Fig. 5 A and C). On the other hand, Ang II 
downregulated the expressions of MMP13 and Runx2 with signiﬁcant 
differences from the control cells (group A) treated with PD123319 
(group E; Fig. 5 B and D). 
4. Discussion 
The existence of a speciﬁc local RAS has been reported in many 
tissues [ 3 ]. However, no report has described the role of a local RAS in 
the hypertrophic differentiation of chondrocytes. In a previous study, 
it was conﬁrmed that AT1R is expressed in cultured osteoblasts [ 11 ]. 
Activating AT1R inhibited differentiation and bone formation in os- 
teoblasts of the rat calvaria [ 10 ]. Unlike AT1R, no signiﬁcant function 
was found for AT2R in such target cells using a speciﬁc blocker [ 10 ]. 
However, AT2R has a reciprocal function to the function of AT1R in 
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Fig. 5. Expression of MMP13 and Runx2 in ATDC5 cells treated with various agents on Day 14. (A) When cells were treated with Olmesartan, Ang II upregulated the mRNA 
expression of MMP13. (B) When cells were treated with PD123319, Ang II downregulated the mRNA expression of MMP13. (C) When cells were treated with Olmesartan, Ang II 
upregulated the mRNA expression of Runx2. (D) When cells were treated with PD123319, Ang II downregulated the mRNA expression of Runx2. The molar concentration ratios of 
antagonists to agonist were 2.32 (1.0 μg / ml Olmesartan / 1.0 μg / ml AngII) and 1.77 (1.0 μg / ml PD123319 / 1.0 μg / ml AngII). * P < 0.05 between treatments. Abbreviations: MMP13, 












































































 many other local and systemic RAS pathways [ 12 ]. For example, AT2R
receptor exerts an antiproliferative effect in vascular smooth muscle,
counteracting the growth action of AT1R [ 13 ]. It was also reported
that AT2R can bind directly to AT1R and thereby antagonizes its func-
tion [ 14 ]. Therefore, we tested the hypothesis that AT2R could have a
function opposite to that of AT1R in the hypertrophic differentiation
of chondrocytes. 
Ang II acts via AT1R and AT2R [ 12 ]. These receptors are mem-
bers of the 7-transmembrane-spanning G protein-coupled receptor
superfamily (GPCRs) [ 15 ]. To activate these receptors separately, we
administered Ang II and Olmesartan or Ang II and PD123319 to the
ATDC5 cell line on Day 14. Olmesartan is a well-known strong AT1R
blocker and also has an inverse agonist activity for AT1R [ 16 , 17 ].
To determine the concentrations of Olmesartan needed, we exam-
ined the separate inﬂuence of adding Olmesartan. Adding 10 μg / ml
Olmesartan upregulated the expression of Col.X without the addition
of AngII. We thought that this interference might arise from Olme-
sartan’s inverse agonist activity for AT1R. Inverse agonist activity is
deﬁned as the ability to block the agonist-independent weak sig-
nal transduction of GRCPs [ 18 ]. AT1R is one of the GPCRs [ 16 ]. AT1R
also induces agonist-independent continuous GRCP signal transduc-
tion [ 19 ]. Namely, the ATDC5 cell line might be affected by weak
internal signals from AT1R, which suppress hypertrophic changes.
By blocking these continuous suppressive signals of AT1R for hyper-
trophy by inverse agonist activity, treatment with 10 μg / ml Olme-
sartan might induce hypertrophic changes. However this treatment
might fully block the AT1R, we did not choose it. We thought that
the use of 10 μg / ml Olmesartan might complicate the experimental
situation because of its own inverse agonist activity. On the other
hand, we could not ﬁnd any separate inﬂuence when adding 0.1 and
1.0 μg / ml Olmesartan. Needing to handle ATDC5 cells without inter-
ference from inverse agonist activity, we chose the dose of 1.0 μg / ml
Olmesartan. We aimed to make the concentration of PD123319 the
same as Olmesartan, because we wanted to equalize the concentra-
tions of these two blockers. Indeed, the molar concentration ratios of
agonists to antagonists were 2.32 (1.0 μg / ml Olmesartan / 1.0 μg / ml
AngII) and 1.77 (1.0 μg / ml PD123319 / 1.0 μg / ml AngII), respectively.
Under these concentration ratios, the receptors might be only par-
tially blocked. On this point, we thought that complete blocking wasnot essential. In previous studies, it was shown that AT1R and AT2R
dominated each other [ 12 , 14 ]; thus, we thought that the relationship
of AT1R to AT2R resembled a seesaw. We considered that even partial
blocking and using agonists could change the ‘balance ’ of the seesaw.
Needing to obtain pure stimulation with AT1R or AT2R, we considered
using agonists with strong selectivity for one receptor, such as Com-
pound 21 [ 20 ]. However, we did not use this approach. Eventually,
we decided that using AngII with blockers was more physiologically
actual than using strong selective artiﬁcial agonists. Under the strong
blockade of AT1R by Olmesartan, Ang II might mainly activate AT2R.
On the other hand, PD123319 is a well-known AT2R blocker. Under
the PD123319’s strong blockade of AT2R, Ang II might primarily ac-
tivate AT1R. When AT1R was activated, the mRNA expression levels
of Col.X, MMP13 and Runx2 were downregulated. On the other hand,
when AT2R was activated, these expression levels were enhanced.
Thus, AT1R acted to suppress hypertrophic chondrocyte differentia-
tion, whereas AT2R activated it. In other words, we conﬁrmed that
AT1R and AT2R showed reciprocal functions in hypertrophic differ-
entiation. The results with administering agents on Day 10 indicated
that AT1R can suppress Col.X expression without the dominance of
AT2R, because this was not expressed on Day 10. Likewise, the results
with administering agents on Day 21 indicated that AT2R can upreg-
ulate Col.X expression without requiring the dominance of AT1R. 
Furthermore, the mRNA expression level of Col.X was downreg-
ulated by adding only Ang II on Day 14. Ang II activated both AT1R
and AT2R. The relative expression of AT1R was much stronger than
that of AT2R at the mRNA level. However, we could not determine
whether AT1R was more strongly expressed than AT2R at the protein
level. There must also be differences in the efﬁciency of translation of
mRNA between AT1R and AT2R. Even in such a situation, the 25-fold
differences at mRNA level might not been reversed during translation.
We also must consider the receptor’s afﬁnities to Ang II. In this study,
we did not measure the afﬁnity of AngII for AT1R and AT2R in the
ATDC5 cell line. However, it has been reported that AngII’s afﬁnity for
AT1R and AT2R is almost equal in other cells [ 21 ]. On the other hand,
there is no report that the AT1R and AT2R expressed on ATDC5 cells
are different from other cells in terms of ligand afﬁnity. Therefore, we
assumed that the afﬁnities for AT1R and AT2R in ATDC5 cells might be
similar. In this way, the signals arising by activating AT1R might have




































Rriority over the signals produced by the activation of AT2R. However, 
his is still only an hypothesis. In this study, our primary focus was on 
eceptor functions. Considering the environment in which chondro- 
ytes live in vivo, it is very uncertain as to whether Ang II is present 
ocally. Chondrocytes usually exist in nonvascular areas. In these ar- 
as, Ang II, which is usually supplied by blood, might be at a low level. 
herefore, Ang II might be supplied by an autocrine system. Because 
e conﬁrmed that the substrate (ANG) and the enzyme (ACE1) were 
xpressed, autocrine-produced Ang II might exist in the chondrocyte 
nvironment. However, we consider that the mainly functional ligand 
f AT receptors on chondrocytes must not be autocrine-derived Ang 
I. We suspect that articular motion is the main cause. Thus, mechan- 
cal stress can activate AT1R without the involvement of Ang II [ 22 ]. 
oreover, shear stress can also activate AT1R [ 23 ]. Considering the 
nvironment that surrounds chondrocytes, we think that mechani- 
al stress is the most reasonable cause. Therefore, we do not think 
hat the presence or absence of Ang II was important in our study. 
n any event, we needed to generate isocratic receptor activation to 
xamine it quantitatively. Therefore, we used Ang II in our study in- 
tead of mechanical stress; however, we should consider using in vivo 
echanical stimulation in future studies. 
In conclusion, activating AT1R suppresses and activating AT2R en- 
ances the hypertrophic differentiation of chondrocytes. Namely, a 
ocal RAS can serve to modulate the hypertrophic differentiation of 
hondrocytes through activating AT1R or AT2R. 
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